雅思阅读Listofheadings题型解题技巧详解

1、第 PAGE12 页 共 NUMPAGES12 页雅思阅读Listofheadings题型解题技巧详解【雅思阅读技巧】List of headings题型解题技巧详解答题技巧：1. 首先在list of headings中划去做为例子的heading 或headings，以免在根据段落内容在list of headings中找出与其相匹配的段落标题时，它(它们)会干扰考试者对其他headings的选择。2. 在文章中把做为例子的段落划掉，以免对例子段落进展不必要的精读。3. 对题目中给出的段落，按照首句(第一、二句)、末句和中间句寻找主题句的顺序的方法，读完段落再读list，在list of

2、headings中找出与其相匹配的段落标题。但是注意，近年来雅思出题有一个趋势，list of headings的题目只有极少数情况下是在首尾有总结句，大局部情况还是需要考生通读全段，总结后比照headings来选择。4. 假如某一个list of headings选项与原文一模一样，完全没有差异的，这个一般不是正确答案，list of headings的题目都是需要略微归纳得出的。5. 对于不确定的答案的段落略微放一放，把确定答案的题目选出来后，利用排除法，选出最贴近段落大意的。6. 注意段落中复杂长句子的表意重点，一般来说，however，but，but also, although, d

3、espite这类词的后面是句子的重点。举例的句子可以略过，一般不会影响答案的选择。7. 要仔细检察答案，特别是第一题型，因为答错一题，就意味着答错两道题。8. 切忌过度推理，headings有时候会出现原文中只有局部表述的内容，用来干扰考生。雅考虑试阅读模拟试题及答案解析1. The failure of a high-profile cholesterol drug has thrown a spotlight on the plicated machinery that regulates cholesterol levels. But many researchers remain co

4、nfident that drugs to boost levels of good cholesterol are still one of the most promising means to bat spiralling heart disease.2. Drug pany Pfizer announced on 2 December that it was cancelling all clinical trials of torcetrapib， a drug designed to raise heart-protective high-density lipoproteins

5、(HDLs)。 In a trial of 15000 patients， a safety board found that more people died or suffered cardiovascular problems after taking the drug plus a cholesterol-lowering statin than those in a control group who took the statin alone.3. The news came as a kick in the teeth to many cardiologists because

6、earlier tests in animals and people suggested it would lower rates of cardiovascular disease. “There have been no red flags to my knowledge，” says John Chapman， a specialist in lipoproteins and atherosclerosis at the National Institute for Health and Medical Research (INSERM) in Paris who has also s

7、tudied torcetrapib. “This cancellation came as a plete shock.”4. Torcetrapib is one of the most advanced of a new breed of drugs designed to raise levels of HDLs， which ferry cholesterol out of artery-clogging plaques to the liver for removal from the body. Specifically， torcetrapib blocks a protein

8、 called cholesterol ester transfer protein (CETP)， which normally transfers the cholesterol from high-density lipoproteins to low density， plaque-promoting ones. Statins， in contrast， mainly work by lowering the bad low-density lipoproteins.Under pressure5. Researchers are now trying to work out why

9、 and how the drug backfired， something that will not bee clear until the clinical details are released by Pfizer. One hint lies in evidence from earlier trials that it slightly raises blood pressure in some patients. It was thought that this mild problem would be offset by the heart benefits of the

10、drug. But it is possible that it actually proved fatal in some patients who already suffered high blood pressure. If blood pressure is the explanation， it would actually be good news for drug developers because it suggests that the problems are specific to this pound. Other prototype drugs that are

11、being developed to block CETP work in a slightly different way and might not suffer the same downfall.6. But it is also possible that the whole idea of blocking CETP is flawed， says Moti Kashyap， who directs atherosclerosis research at the VA Medical Center in Long Beach， California. When HDLs excre

12、te cholesterol in the liver， they actually rely on LDLs for part of this process. So inhibiting CETP， which prevents the transfer of cholesterol from HDL to LDL， might actually cause an abnormal and irreversible accumulation of cholesterol in the body. “Youre blocking a physiologic mechanism to elim

13、inate cholesterol and effectively constipating the pathway，” says Kashyap.Going up7. Most researchers remain confident that elevating high density lipoproteins levels by one means or another is one of the best routes for helping heart disease patients. But HDLs are plex and not entirely understood.

14、One approved drug， called niacin， is known to both raise HDL and reduce cardiovascular risk but also causes an unpleasant sensation of heat and tingling. Researchers are exploring whether they can bypass this side effect and whether niacin can lower disease risk more than statins alone. Scientists a

15、re also working on several other means to bump up high-density lipoproteins by， for exle， introducing synthetic HDLs. “The only thing we know is dead in the water is torcetrapib， not the whole idea of raising HDL，” says Michael Miller， director of preventive cardiology at the University of Maryland

16、Medical Center， Baltimore.Questions 1-7This passage has 7 paragraphs 1-7.Choose the correct heading for each paragraph from the list of headings below.Write the correct number i-ix in boxes 1-7 on your answer sheet.List of Headingsi. How does torcetrapib work?ii. Contradictory result prior to the cu

17、rrent trialiii. One failure may possibly bring about future successiv. The failure doesnt lead to total loss of confidencev. It is the right route to followvi. Why its stoppedvii. They may bine and theoretically produce ideal resultviii. Whats wrong with the drugix. It might be wrong at the first pl

18、aceQuestions 7-13Match torcetrapib，HDLs，statin and CETP with their functions (Questions 8-13)。Write the correct letter A， B， C or D in boxes 8-13 on your answer sheet.NB You may use any letter more than once.7.It has been administered to over 10，000 subjects in a clinical trial.8.It could help rid h

19、uman body of cholesterol.9.Researchers are yet to find more about it.10. It was used to reduce the level of cholesterol.11. According to Kashyap， it might lead to unwanted result if its blocked.12. It produced contradictory results in different trials.13. It could inhibit LDLs.List of choicesA. TorcetrapicB. HDLSC. StatinD. CETPSuggested Answers and Explanations1. vi2. ii3. vii 本段介绍了torcetrapib和statin的治病原理，但是同时短语“in contrast”与之前第二段后半段的内容照应，暗示了这两种药在理论上能相辅相成，是理想的搭配。第一个选项无法涵盖整段意义，应选择i是错误的。4. iii 本段分析p 了可能导致torcetrapibl临床试验失败的原因，后半段指出假如以上推测正确，那么将来的药